Regis Healthcare (ASX:REG) Share Price Falls As Profits Slump

Shares of aged care operator Regis Healthcare Ltd (ASX: REG) were on watch yesterday after the company released its 2019 financial results.

Regis said negative sentiment towards the aged care industry has contributed to a 17% decline in its FY19 profit.

Formed in 1994, Regis is one of Australia’s largest providers of aged care services with more than 6,000 residents calling Regis home throughout Australia.

Regis’ FY19 Results

Regis recorded net profit after tax (NPAT) of $50.9 million for the 2019 financial year. The company has provided a normalised set of results to account for the Royal Commission costs incurred during the period and a non cash fair value gain on two non-operating retirement living sites as a result of a re-evaluation of company assets. Normalised net profit came in at $47.2 million.

Revenue of $647.1 million has translated into normalised earnings before interest, tax, depreciation and amortisation (EBITDA) of $111.4 million.

The average occupancy rate for its properties came in at 92.7%, which is slightly below the 93.6% reported by fellow aged care provider Estia Health Ltd (ASX: EHE) earlier this week.

The company managed to strengthen its balance sheet during the year, reducing net debt by $101 million to close at $303.2 million as at June 30.

The company has declared a final dividend of 7.11 cents per share which is 18% lower than the same time last year. Adding the 8.12 cent interim dividend, the full year dividend comes out at 15.23 cents per share, which places Regis shares on a trailing dividend yield of 5.4%.

Regis said the full year results were negatively impacted by the Royal Commission and the ongoing negative sentiment towards the industry as a result. The company said this also coincided with a significant increase in supply with a large number of new home care places opening up during the period.

Outlook For FY20

Regis has reiterated its guidance for FY20 EBITDA of circa $105 million, which represents a 5% decline on yesterday’s result. This figure includes a circa $3 million impact from one-off costs relating to the implementation of regulatory changes that came into effect from 1 July 2019 as a result of the Royal Commission findings.

The company said normalised net profit is expected to be approximately $38 million. This may have disappointed shareholders as it constitutes a fall of nearly 20% on the FY19 result.

Is It Time To Buy Regis Shares?

I thought the Regis result was a bit disappointing and the profit guidance for FY20 hardly inspires confidence. I am also wary that there may still be more bad news to come from the fallout of the Royal Commission.

If I were interested in buying shares in one of the ASX listed aged care providers, I would be waiting at least 6 months to let the dust settle before pulling the trigger.

At the time of publishing, Luke has no financial interest in any companies mentioned.

Free report: 3 cloud stocks to buy now

As we emerge from COVID-19, some tech companies are growing faster than ever. Rask’s investment analysts have identified 3 growth stocks set to benefit. Big time.

We’ll send you our report for free, including the names, ticker codes and analysis when you enter your email address below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Free report: 3 cloud stocks to buy now

As we emerge from COVID-19, some tech companies are growing faster than ever. Rask’s investment analysts have identified 3 growth stocks set to benefit. Big time.

Click here to access this report for free, including the names, ticker codes and analysis.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: